Companies are deploying siRNA and antisense oligonucleotides to tackle dangerously high cholesterol driven by genetics, betting that a wider population will benefit.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Targeting Lipoprotein(a): Can RNA Therapeutics Provide the Next Step in the Prevention of Cardiovascular Disease?
Cardiology and Therapy Open Access 21 February 2024
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Sheridan, C. RNA drugs lower lipoprotein(a) and genetically driven cholesterol. Nat Biotechnol 40, 983–985 (2022). https://doi.org/10.1038/s41587-022-01396-x
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41587-022-01396-x
This article is cited by
-
Targeting Lipoprotein(a): Can RNA Therapeutics Provide the Next Step in the Prevention of Cardiovascular Disease?
Cardiology and Therapy (2024)